Skip to Main Content
Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are doing reasonably well so far, thank you. Despite the chaos swirling about and decidedly gloomy skies, we think of what the Morning Mayor taught us: Every new day should be unwrapped like a precious gift. So go ahead and tug on the ribbon. Meanwhile, we will brew another cup of stimulation — and follow directions for a healthier outcome, too. Please feel free to join us. And of course, here are some items of interest to help you along. Have a productive day and keep safe. …

Rick Bright, who was ousted from the top job at BARDA this week, has decided to put the Trump administration on trial and the charge is politicizing science, STAT explains. In his telling, he is the first clear casualty of a White House war on the scientific process, unceremoniously demoted for refusing to invest federal money in an untested coronavirus therapy that President Trump has nonetheless embraced. He alleges, too, that he had to resist “efforts to fund potentially dangerous drugs promoted by those with political connections.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.